Elanco Animal Health (NYSE:ELAN) Insider Acquires $95,985.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Rajeev Modi acquired 4,500 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the acquisition, the insider directly owned 123,082 shares in the company, valued at $2,625,339.06. This represents a 3.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Elanco Animal Health Stock Up 2.0%

NYSE:ELAN traded up $0.43 on Monday, reaching $21.72. The stock had a trading volume of 5,970,920 shares, compared to its average volume of 5,860,102. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $23.70. The stock has a market cap of $10.79 billion, a P/E ratio of 361.98, a price-to-earnings-growth ratio of 2.89 and a beta of 1.86. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $21.73 and a 200 day moving average of $18.10.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the firm posted $0.13 earnings per share. The company’s revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Wednesday, November 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 8th. Barclays started coverage on shares of Elanco Animal Health in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price on the stock. Zacks Research downgraded Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Finally, Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.78.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors have recently modified their holdings of the business. Cetera Investment Advisers lifted its holdings in Elanco Animal Health by 7.2% in the first quarter. Cetera Investment Advisers now owns 33,234 shares of the company’s stock worth $349,000 after acquiring an additional 2,230 shares during the last quarter. LPL Financial LLC raised its position in shares of Elanco Animal Health by 23.8% during the 1st quarter. LPL Financial LLC now owns 199,595 shares of the company’s stock worth $2,096,000 after purchasing an additional 38,412 shares during the period. US Bancorp DE lifted its holdings in shares of Elanco Animal Health by 18.7% in the 1st quarter. US Bancorp DE now owns 14,906 shares of the company’s stock worth $157,000 after purchasing an additional 2,346 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Elanco Animal Health by 14.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 13,404 shares of the company’s stock valued at $141,000 after purchasing an additional 1,641 shares during the period. Finally, Invesco Ltd. grew its stake in Elanco Animal Health by 3.5% during the 1st quarter. Invesco Ltd. now owns 555,262 shares of the company’s stock worth $5,830,000 after buying an additional 18,871 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.